FA864924P0722
Purchase Order
Overview
Government Description
CLEARANCE OF PATHOGENS CAUSING DIARRHEA, DYSENTERY AND URINARY TRACT INFECTIONS
Awardee
Awarding / Funding Agency
Place of Performance
Reno, NV 89508 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Research Type
Small Business Innovation Research Program (SBIR) Phase I
Related Opportunity
None
Theralytix was awarded
Purchase Order FA864924P0722 (FA8649-24-P-0722)
for Clearance Of Pathogens Causing Diarrhea, Dysentery And Urinary Tract Infections
worth up to $70,888
by Air Force Research Laboratory
in June 2024.
The contract
was awarded
with a Small Business Total set aside
with
NAICS 541715 and
PSC AC32
via direct negotiation acquisition procedures with 999 bids received.
Status
(Complete)
Last Modified 6/26/24
Period of Performance
6/26/24
Start Date
9/24/24
Current End Date
9/24/24
Potential End Date
Obligations
$70.9K
Total Obligated
$70.9K
Current Award
$70.9K
Potential Award
Award Hierarchy
Purchase Order
FA864924P0722
Subcontracts
Activity Timeline
People
Suggested agency contacts for FA864924P0722
Competition
Number of Bidders
Not Applicable For Award Type
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Performance Based Acquisition
Yes
Commercial Item Acquisition
Commercial Item
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Defense Program
None
DoD Claimant Code
None
IT Commercial Item Category
Not Applicable
Awardee UEI
Q2P9NPCFSDC7
Awardee CAGE
95TY3
Agency Detail
Awarding Office
FA8649 FA8649 USAF SBIR STTR CONTRACTING
Funding Office
F4FBEQ
Created By
joshua.ortiz.3@us.af.mil
Last Modified By
michael.bonham.1@us.af.mil
Approved By
michael.bonham.1@us.af.mil
Legislative
Legislative Mandates
None Applicable
Performance District
NV-02
Senators
Catherine Cortez Masto
Jacky Rosen
Jacky Rosen
Representative
Mark Amodei
Modified: 6/26/24